Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Post-COVID-19 Syndrome (VERI-LONG)
NCT05697640Phase 2Active, not recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jun 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Vericiguat oral suspension (Formulation 4) in Post COVID-19 Syndrome (PCS) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Short Form 36 Health Survey Questionnaire Physical Function at 10 weeks. Started Jun 2023; status: active, not recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
Post COVID-19 Syndrome (PCS)
Beyond the preview
Go deeper on NCT05697640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05697640.